Drug Trial Radar · NCT06534983
A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC)
Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
62
Planned (sponsor's estimate)
Start
Dec 9, 2024
Primary completion
Nov 10, 2027
Study completion Nov 10, 2027
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- Collaborators
- BioNTech SE
- First posted
- Aug 2, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The original purpose of this study was to evaluate the efficacy of adjuvant treatment with autogene cevumeran plus nivolumab compared with nivolumab in participants with high risk MIUC. In this study participants will be enrolled in a safety run-in phase to receive autogene cevumeran + nivolumab. This phase will be conducted to monitor and ensure the safety of study participants. After all participants in the safety run-in have been enrolled to receive autogene cevumeran + nivolumab, further participants will be randomized in either autogene cevumeran + nivolumab or the nivolumab monotherapy arm. Following the Sponsor's decision to phase out the study, as of Protocol Version 5, the primary purpose of the study is to ensure treatment continuity and safety for the participants who continue to participate in the study and receive study treatment.
Conditions
- Muscle-invasive Urothelial Carcinoma
Interventions
Autogene CevumeranDrug
Autogene cevumeran will be administered as an IV infusion per the schedule specified in the arm.
NivolumabDrug
Nivolumab will be administered as an IV infusion per the schedule specified in the arm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Adverse Events (AEs)Time frame: Up to approximately 15 months
Locations
38 sites in 15 countries. Site status is shown where the registry gives one.
Memorial Sloan Kettering Cancer Center Basking Ridge
Basking Ridge, New Jersey
MSK Monmouth
Middletown, New Jersey
MSK Bergen
Montvale, New Jersey
MSK Commack
Commack, New York
MSK Westchester
Harrison, New York
Memorial Sloan Kettering Cancer Center
New York, New York
MSK Nassau
Uniondale, New York
Hospital Italiano
Ciudad Autonoma Buenos Aires, Argentina
Lyell McEwin Hospital
Elizabeth Vale, South Australia, Australia
Jewish General Hospital
Montreal, Quebec, Canada
McGill University Health Center
Montreal, Quebec, Canada
Aalborg Universitetshospital
Aalborg, Denmark
Aarhus Universitetshospital
Aarhus N, Denmark
Herlev Hospital
Herlev, Denmark
Vivantes Klinikum Am Urban
Berlin, Germany
Uniklinikum Heidelberg
Heidelberg, Germany
Marien Hospital Herne
Herne, Germany
Klinikum Stuttgart - Katharinenhospital
Stuttgart, Germany
Theageneio Hospital
Thessaloniki, Greece
A.O. Universitaria Ospedale Consorziale Policlinico Di Bari
Bari, Apulia, Italy
IFO - Istituto Regina Elena
Rome, Lazio, Italy
A.O. Universitaria S. Luigi Gonzaga
Orbassano, Piedmont, Italy
A.O.U di Verona Policlinico G.B. Rossi
Verona, Veneto, Italy
Akershus universitetssykehus
Lørenskog, Norway
Centrum Onkologii im. Prof. Franciszka ?ukaszczyka
Bydgoszcz, Poland
AIDPORT Sp. z o. o.
Skórzewo, Poland
Seoul National University Bundang Hospital
Seongnam-si, South Korea
Seoul National University Hospital
Seoul, South Korea
Asan Medical Center
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
Hospital Clinico San Carlos
Madrid, Spain
Hospital Universitario Virgen del Rocio
Seville, Spain
Hospital Clinico Universitario Lozano Blesa
Zaragoza, Spain
ICO L'Hospitalet
L'Hospitalet de Llobregat, Barcelona, Spain
Vall d'Hebron Institute of Oncology (VHIO), Barcelona
Sant Andreu de la Barca, Barcelona, Spain
Sahlgrenska University Hospital
Gothenburg, Sweden
Chang Gung Medical Foundation - Kaohsiung
Kaohisung, Taiwan
Barts & London School of Med;Medical Oncology
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.